Bortezomib is an effective inhibitor of neuroblastoma cell growth and angiogenesis. These findings provide the rationale for further clinical investigation of bortezomib in pediatric neuroblastoma.
No takes yet. Share an insight, caveat, or question.
Brignole et al. (2006) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: